CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


RESP301, a Nitric Oxide generating solutionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2476 Tested for SARS-CoV-2 (regardless of the result) Wiki 1.00
drug583 Clinical diagnosis of COVID-19 by a health care professional Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 NOCoV2 - An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 Requiring Supplemental Oxygen

The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19 patients.

NCT04460183 COVID-19 Drug: RESP301, a Nitric Oxide generating solution Other: Standard of Care

Primary Outcomes

Measure: Proportion of participants who progress to level >4 of modified WHO ordinal scale due to COVID-19 by Day 14

Time: From Day 1 to Day 14

Secondary Outcomes

Measure: Change in room air oxygen saturation (SpO2) from baseline over time

Time: Baseline to Day 28

Measure: Change in National Early Warning Score (NEWS) 2 symptom score from baseline over time

Time: Baseline to Day 28

Measure: Change from baseline on the modified WHO ordinal scale at each visit up to Day 28

Time: Baseline to Day 28

Measure: Time to improvement to a lower level (<4) of modified WHO ordinal scale

Time: Baseline to Day 28

Measure: Time to progression to a higher level (>4) of modified WHO ordinal scale

Time: Baseline to Day 28

Measure: Number of participants with adverse events and serious adverse events

Time: Baseline to Day 28


No related HPO nodes (Using clinical trials)